Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 2416 to 2430 of 8221 results

  1. Artificial Intelligence in MRI for prostate cancer diagnosis

    Awaiting development Reference number: GID-HTE10089 Expected publication date: TBC

    Health technology evaluations
    Awaiting development

  2. Aficamten for treating symptomatic obstructive hypertrophic cardiomyopathy ID6575

    In development Reference number: GID-TA11742 Expected publication date: TBC

    Technology appraisal guidance
    In development

  3. Talazoparib with enzalutamide for untreated hormone-relapsed metastatic prostate cancer [ID4004]

    In development Reference number: GID-TA10904 Expected publication date:  03 December 2025

    Technology appraisal guidance
    In development

  4. Durvalumab with platinum-based chemotherapy, then with or without olaparib, for treating newly diagnosed advanced or recurrent endometrial cancer ID6317

    In development Reference number: GID-TA11340 Expected publication date: TBC

    Technology appraisal guidance
    In development

  5. Teplizumab for delaying the onset of stage 3 type 1 diabetes in people 8 years and over with stage 2 type 1 diabetes [ID6259]

    In development Reference number: GID-TA10981 Expected publication date:  08 April 2026

    Technology appraisal guidance
    In development

  6. Digital platforms to support rehabilitation before and after primary elective hip or knee replacement surgery

    In development Reference number: GID-HTE10069 Expected publication date:  11 August 2026

    Health technology evaluations
    In development

  7. Plozasiran for treating familial chylomicronaemia syndrome [ID6593]

    In development Reference number: GID-TA11793 Expected publication date:  18 November 2026

    Technology appraisal guidance
    In development

  8. Endoscopic submucosal dissection knives for the resection of complex colorectal polyps with suspected submucosal invasion

    In development Reference number: GID-HTE10072 Expected publication date:  19 November 2026

    Health technology evaluations
    In development

  9. Ex-situ machine perfusion devices for extracorporeal preservation of lungs for transplant

    In development Reference number: GID-HTE10084 Expected publication date: TBC

    Health technology evaluations
    In development

  10. Decitabine–cedazuridine with venetoclax for treating acute myeloid leukaemia when intensive induction chemotherapy is unsuitable [ID6601]

    Awaiting development Reference number: GID-TA11765 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  11. SpaceOAR hydrogel spacer for reducing rectal toxicity during radiotherapy for prostate cancer (Suspended – referred to technology appraisals)

    In development Reference number: GID-MT526 Expected publication date: TBC

    Medical technologies guidance
    In development

  12. Givinostat for treating Duchenne muscular dystrophy in people 6 years and over [ID6323]

    In development Reference number: GID-TA11373 Expected publication date: TBC

    Technology appraisal guidance
    In development

  13. Domestic Abuse: draft scope consultation

    We are listening to your views on this NICE guideline. Comments close 27 January 2026.

    NICE guideline
    In consultation

  14. Sutimlimab for treating haemolytic anaemia in people with cold agglutinin disease [ID6673]

    Awaiting development Reference number: GID-TA11892 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  15. Giredestrant with everolimus for treating oestrogen-receptor positive HER2-negative advanced breast cancer after cyclin-dependent kinase 4 and 6 inhibitor and endocrine treatment ID6576

    In development Reference number: GID-TA11773 Expected publication date: TBC

    Technology appraisal guidance
    In development